Product Name | CKS-17 |
Product Quantity | 5mg |
Catalog Number | LT1263 |
Molecular Weight | 1942.31 |
Formula | C87H148N26O24 |
Sequence | Leu-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu |
Product Description | CKS-17 peptide corresponds to aa 533-549 of the murine leukemia virus (MLV) envelope protein, the immunosuppressive region present in any retroviral envelope proteins. The CKS-17 peptide has been previously shown to inhibit monocyte superoxide production, natural killer cell activity, polyclonal B-cell activation, and monocyte-mediated killing by inactivation of interleukin-1. |
Scientific Background | CKS-17 is a 17-residue synthetic peptide with the sequence Leu-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu. The sequence contains 1 Lys and 2 Arg residues, contributing cationic character. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Research Applications | - LC-MS/HPLC analytical method development
- sequence-specific assay controls
|
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
